The Employees' State Insurance Corporation (ESIC) on November 11, 2026, has initiated the process of preparing replacement Central Rate Contracts for drugs and medicines covered under DG-ESIC Rate Contract Nos. 159, 160, 161, 162, 163 and 164, which are valid until April 7, 2027. Accordingly, ESIC institutions have been invited to submit recommendations for the addition, deletion and modification of drug specifications in the existing drug schedule.
For the inclusion of new drugs, Deans/Medical Superintendents/DIMS must obtain recommendations from the respective department heads, supported by justification regarding the absence of equivalent generic alternatives, clinical advantages and relevant published references. Recommendations must also include authenticated local purchase and consumption data for September 2025 to October 2026, with a minimum eligibility criterion of cumulative expenditure of ₹25,000 or consumption of 25,000 units at the institutional level, including tagged dispensaries. For deletion of existing drugs, procurement details for the preceding year and justification from the concerned departments must be provided. Proposed modifications in drug specifications must be supported by valid reasons and documentary evidence, including WHO recommendations or Government Orders, wherever applicable.
The Institution Heads (Dean/MS/DIMS) are required to consolidate and verify the recommendations received from respective departments and submit separate consolidated lists for additions and deletions, along with proposals for specification modifications, by December 9, 2026, through email at [email protected].
[Notification No. U-25/12/RC-176to181/2026-Medical.V (1829485)/340]
